ZDHHC11B is a putative palmitoyltransferase that catalyzes palmitate addition to protein substrates, with emerging roles in cancer biology and immune regulation. The protein localizes to the endoplasmic reticulum and Golgi apparatus and possesses protein-cysteine S-palmitoyltransferase activity 1. In lung adenocarcinoma (LUAD), ZDHHC11B functions as a tumor suppressor. Overexpression inhibits cell proliferation, migration, and invasion while inducing apoptosis in LUAD cells and suppressing tumor growth in vivo 1. Mechanistically, ZDHHC11B inhibits tumorigenesis by regulating epithelial-mesenchymal transition (EMT), as demonstrated by suppression of EMT molecular markers under ZDHHC11B overexpression conditions 1. Clinically, ZDHHC11B shows reduced expression in LUAD tissues and is identified as a prognostic biomarker in non-small cell lung cancer (NSCLC), where downregulation correlates with poor outcomes 2. Additionally, ZDHHC11B was identified as a candidate pancreatic cancer susceptibility gene through transcriptome-wide association analysis, suggesting broader oncogenic relevance 3. The gene was also detected with focal chr5 amplification in external auditory canal squamous cell carcinoma 4. These findings position ZDHHC11B as a potential molecular target for cancer therapeutics, particularly through EMT regulation in lung malignancies.